Please use this identifier to cite or link to this item:
|Title:||Morbidity rates with reduced mycophenolate mofetil dosage: a single-center experience.|
|Citation:||TRANSPLANT PROC, 2006, 38 (9), pp. 2864-2865|
|Abstract:||Mycophenolate Mofetil (MMF) is a key component of available immunosuppressant regimens for transplantation. Traditionally a dose of 2 g/d is utilized, with the incidence of side effects, most notably gastrointestinal, being well known to transplant teams. The aim of this study was to assess the incidence of side effects and rejection rates with reduced doses compared to standard regimens of MMF.|
|Appears in Collections:||Published Articles, Dept. of Infection, Immunity and Inflammation|
Files in This Item:
There are no files associated with this item.
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.